Finance

Lists
Why is TARA down 5.03%?
Dive Deeper
TARA:NASDAQ
Protara Therapeutics Inc
$3.50
-5.03%
(-0.19) 1D
Sep 23, 12:03:21 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TARA...
Open
$3.69
High
$3.75
Low
$3.48
Mkt. cap
206.54M
Avg. vol.
677.28K
Volume
308.37K
52-wk high
$7.82
52-wk low
$3.45
EPS
-$1.35
Beta
1.49
Shares outstanding
59.10M
No. of employees
46
Open
$3.69
High
$3.75
Low
$3.48
Mkt. cap
206.54M
Avg. vol.
677.28K
Volume
308.37K
52-wk high
$7.82
52-wk low
$3.45
EPS
-$1.35
Beta
1.49
Shares outstanding
59.10M
No. of employees
46
About Protara Therapeutics Inc
CEO-
Employees46
Founded2006
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to TARA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TARA in the last 3 months.
Highest
Current $3.50
$27.00 (+672.53%)
Average
$24.00 (+586.70%)
Lowest
$20.00 (+472.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$27.00
+672.5%
09/21/2026
Boris Peaker
JonesTrading
Buy
Maintained
$25.00
+615.3%
08/11/2026
Charles Zhu
LifeSci Capital
Buy
Reiterated
$20.00
+472.2%
08/11/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
-
-
06/30/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$24.00
+586.7%
05/20/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$28.00
+701.1%
05/20/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$28.00
+701.1%
05/20/2026
Stacy Ku
TD Cowen
Buy
Reiterated
-
-
05/20/2026
Soumit Roy
JonesTrading
Buy
Maintained
$25.00
+615.3%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.59M
13.12M
13.56M
16.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.17M
5.96M
6.07M
6.37M
Operating expense
14.76M
19.08M
19.63M
23.32M
Total operating expenses
14.76M
19.08M
19.63M
23.32M
Operating income
-14.76M
-19.08M
-19.63M
-23.32M
Other non operating income
-
249.00K
-
-
EBT including unusual items
-13.26M
-17.31M
-17.78M
-21.67M
EBT excluding unusual items
-13.26M
-17.31M
-17.78M
-21.67M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.26M
-17.31M
-17.78M
-21.67M
Net profit margin
-
-
-
-
Earnings per share
-0.31
-0.38
-0.31
-0.36
Interest and investment income
1.50M
1.52M
1.85M
1.66M
Interest expense
-
-
-
-
Net interest expenses
1.50M
1.52M
1.85M
1.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.67M
-18.99M
-19.54M
-23.25M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps